Ibrance® (palbociclib) – New formulation approval
November 1, 2019 - The FDA approved an oral tablet formulation of Pfizer’s Ibrance (palbociclib), for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men; or Fulvestrant in patients with disease progression following endocrine therapy.
Top